Your browser doesn't support javascript.
loading
MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells.
Tomei, Sara; Volontè, Andrea; Ravindran, Shilpa; Mazzoleni, Stefania; Wang, Ena; Galli, Rossella; Maccalli, Cristina.
Afiliación
  • Tomei S; Research Department, Sidra Medicine, Doha PO26999, Qatar.
  • Volontè A; Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, Division of Molecular Oncology, San Raffaele Foundation Scientific Institute, 20132 Milan, Italy.
  • Ravindran S; Research Department, Sidra Medicine, Doha PO26999, Qatar.
  • Mazzoleni S; Neural Stem Cell Biology Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Wang E; Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, and Center for Human Immunology (CHI) National Institutes of Health, Bethesda, MD 20892, USA.
  • Galli R; Neural Stem Cell Biology Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Maccalli C; Research Department, Sidra Medicine, Doha PO26999, Qatar.
J Pers Med ; 11(4)2021 Apr 01.
Article en En | MEDLINE | ID: mdl-33916317
ABSTRACT
Glioblastoma (GBM) represents the most common and aggressive tumor of the brain. Despite the fact that several studies have recently addressed the molecular mechanisms underlying the disease, its etiology and pathogenesis are still poorly understood. GBM displays poor prognosis and its resistance to common therapeutic approaches makes it a highly recurrent tumor. Several studies have identified a subpopulation of tumor cells, known as GBM cancer stem cells (CSCs) characterized by the ability of self-renewal, tumor initiation and propagation. GBM CSCs have been shown to survive GBM chemotherapy and radiotherapy. Thus, targeting CSCs represents a promising approach to treat GBM. Recent evidence has shown that GBM is characterized by a dysregulated expression of microRNA (miRNAs). In this study we have investigated the difference between human GBM CSCs and their paired autologous differentiated tumor cells. Array-based profiling and quantitative Real-Time PCR (qRT-PCR) were performed to identify miRNAs differentially expressed in CSCs. The Cancer Genome Atlas (TCGA) data were also interrogated, and functional interpretation analysis was performed. We have identified 14 miRNAs significantly differentially expressed in GBM CSCs (p < 0.005). MiR-21 and miR-95 were among the most significantly deregulated miRNAs, and their expression was also associated to patient survival. We believe that the data provided here carry important implications for future studies aiming at elucidating the molecular mechanisms underlying GBM.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2021 Tipo del documento: Article País de afiliación: Qatar

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2021 Tipo del documento: Article País de afiliación: Qatar